NEW DELHI, 18 October 2026 — From 9 November 2026, the gap between the price at which 137 non-scheduled anti-cancer drugs leave the first point of sale and the MRP printed on the pack may not exceed 30% of that MRP, under a National Pharmaceutical Pricing Authority order notified on 17 October, the Department of…


